Site icon OncologyTube

SWOG S1500 – Randomized Phase II Trial Efficacy assessment of multiple MET kinase inhibitors in metastatic PRCC

Brian M. Shuch, MD Yale School of Medicine, discusses the SWOG S1500 – Randomized Phase II Trial Efficacy assessment of multiple MET kinase inhibitors in metastatic PRCC at Kidney Cancer Association 2017 in Miami.

Exit mobile version